

## BRIEF REPORT

# The Cerebellar Cognitive-Affective Syndrome Scale Reveals Consistent, Early, and Progressive Neuropsychological Deficits in Autosomal-Recessive Spastic Ataxia of Charlevoix-Saguenay: A Large International Cross-Sectional Study

Julie Fortin, PhD,<sup>1,2</sup> Matthis Synofzik, MD,<sup>3,4</sup> Élyse-Anne Pedneault-Tremblay, OT,<sup>1</sup> Dominik Hermle,<sup>3</sup> Andreas Thieme, MD,<sup>5</sup> Dagmar Timmann, MD,<sup>5</sup> Roberta La Piana, MD, PhD,<sup>6</sup> Bernard Brais, MD, PhD,<sup>6</sup> Justine Dolbec, MS,<sup>1</sup> Isabelle Côté, MS,<sup>1</sup> Cynthia Gagnon, OT, PhD,<sup>1,2,7,8\*</sup> and Andreas Traschütz, MD, PhD<sup>3,4</sup>

**ABSTRACT: Background:** Neuropsychological deficits have been observed in patients with cerebellar damage, but never thoroughly investigated in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).

**Objectives:** The goal is the characterization of presence, severity, and profile of neuropsychological deficits in ARSACS using the cerebellar cognitive-affective syndrome (CCAS) scale.

**Methods:** Prospective study including a discovery cohort from Saguenay/Canada (n = 31, median [inter-quartile

range] age: 57 [54–62] years), and a validation cohort from Tübingen, Germany (n = 17, 35 [21–43] years) with matched controls (n = 19).

**Results:** All ARSACS patients failed in multiple CCAS-related subtests and exceeded cutoffs for “definite CCAS.” Even the younger validation cohort failed more subtests than controls (5 [3–7] vs. 1 [1–2],  $P < 0.001$ ) and had lower CCAS total scores (81 [67–86] vs. 101 [91–106],  $P < 0.001$ ). Total scores worsened in the older discovery cohort (40 [25–52],  $P < 0.001$ ) and correlated with age/disease duration ( $\rho = -0.575$ ,  $P < 0.001$ ) and

<sup>1</sup>Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires (GRIMN), Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-St-Jean, Hôpital de Jonquière, Saguenay, Québec, Canada; <sup>2</sup>Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Québec, Canada; <sup>3</sup>Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany; <sup>4</sup>German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; <sup>5</sup>Department of Neurology and Center for Translational Neuro- and Behavioral Studies Sciences (C-TNBS), Essen University Hospital Essen, University of Duisburg-Essen, Essen, Germany; <sup>6</sup>Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada; <sup>7</sup>Centre de Recherche et d'Innovation du Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-St-Jean, Clinique des Maladies Neuromusculaires, Hôpital de Jonquière, Saguenay, Québec, Canada; <sup>8</sup>Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), Université de Sherbrooke, Sherbrooke, Quebec, Canada

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](#) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

**\*Correspondence to:** Cynthia Gagnon, Groupe de Recherche Interdisciplinaire sur les Maladies Neuromusculaires, 2230 de l'Hôpital PO Box 1200, Jonquière, QC G7X 7X2, Canada; E-mail: [cynthia.gagnon4@usherbrooke.ca](mailto:cynthia.gagnon4@usherbrooke.ca)

Julie Fortin and Matthis Synofzik authors are joint first authors.

Cynthia Gagnon and Andreas Traschütz authors are joint last authors.

**Financial Disclosures and Conflicts of Interest:** C.G. has received consultancy honoraria from Biogen Idec, and acts as a consultant for

Seelos, Dyne, and Lupin. She also conducts academic work for Biogen Idec, Ionis, Seelos, and Vertex, all unrelated to the present manuscript. M.S. has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Solaxa, Quince, and Lilly, all unrelated to the present manuscript. All other authors have no competing interests to disclose.

**Funding agencies:** This study was supported as part of the PROSPAX consortium under the frame of the European Joint Programme on Rare Diseases (EJP RD), under the EJP RD COFUND-EJP no. 825575 (by the Deutsche Forschungsgemeinschaft; to C.G., M.S., B.B., and R.S.); and as part of the EJP RD consortium TREAT-ARCA (BMBF, 01GM2005) (to M.S. and B.B.), also in the frame of the European Union's Horizon 2020 research and innovation program under the EJP RD COFUND-EJP no. 825575; by the European Union, project European Rare Disease Research Alliance (ERDERA), GA no. 101156595, funded under call HORIZON-HLTH-2023-DISEASE-07 (to M.S. and A.T.); and by the Clinician Scientist program ‘PRECISE.net’ funded by the Else Kröner-Fresenius-Stiftung (to A.T. and M.S.). This study received support from the Consortium international, including the Canadian Institutes of Health Research, Ataxia Charlevoix-Saguenay Foundation and Muscular Dystrophy Canada. An.Th. received research grants by the German Heredo-Ataxia Society (Deutsche Heredo-Ataxie-Gesellschaft e.V.), “Freunde und Förderer der Neurologie der Universitätsmedizin Essen” and a scholarship of UMEA/DFG (University Medicine Essen Clinician Scientist Academy—a program funded by Deutsche Forschungsgemeinschaft, German Research Foundation; FU356/12–1 and FU356/12–2).

**Received:** 14 October 2025; **Revised:** 17 December 2025; **Accepted:** 5 January 2026

Published online 11 February 2026 in Wiley Online Library ([wileyonlinelibrary.com](http://wileyonlinelibrary.com)). DOI: 10.1002/mds.70201

ataxia severity (Scale for the Assessment and Rating of Ataxia:  $\rho = -0.527$ ,  $P = 0.003$ ).

**Conclusions:** Neuropsychological deficits consistent with CCAS are consistent in ARSACS, present early, and progress in the disease course. © 2026 The Author(s). *Movement Disorders* published by Wiley Periodicals LLC

on behalf of International Parkinson and Movement Disorder Society.

**Key Words:** cognition; cerebellar cognitive-affective syndrome; movement disorders; neuropsychology; spastic ataxia of Charlevoix-Saguenay

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a frequent recessive ataxia worldwide.<sup>1,2</sup> ARSACS involves progressive degeneration of the cerebellum, corticospinal tract and peripheral nerves, and leads to motor manifestations such as limb incoordination, dysarthria, and impaired mobility.<sup>3,4</sup> Recent studies also observed neuropsychological deficits in ARSACS (eg, reduced verbal learning, processing speed, visuospatial ability, and mental rigidity).<sup>5-9</sup> These deficits are possibly linked to the cerebellar cognitive-affective syndrome (CCAS), which is characterized by impaired executive functions, linguistic processing, visuospatial function, and affect regulation.<sup>10-12</sup> CCAS has been described after acquired cerebellar damage and in several genetic ataxias,<sup>13-23</sup> but not systematically in ARSACS. However, characteristics of neuropsychological deficits need to be better understood in ARSACS, as cognitive-affective rigidity and poor self-awareness are related to employment in ARSACS,<sup>24</sup> and because neuropsychological deficits likely affect the validity of patient-reported outcomes in upcoming treatment trials.

Therefore, this large prospective cross-sectional international bi-center study systematically explored the presence, severity, and profile of neuropsychological deficits in 48 ARSACS patients using the Cerebellar Cognitive-Affective Syndrome scale (CCAS scale)—a scale developed for a targeted screening for the syndrome in cerebellar disorders.<sup>20</sup> The study leverages an aged discovery cohort from Saguenay (Canada) and a younger independent validation cohort with a different geographic and heterogeneous genetic background. Onset, progression, and relation to motor impairment of neuropsychological deficits are characterized by comparison with matched controls and correlation with ataxia severity.

## Patients and Methods

Forty-eight patients with genetically confirmed ARSACS and able to give free and informed consent were recruited at two centers: a “discovery cohort” ( $n = 31$ ) at the Neuromuscular Clinic of the Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-St-Jean (Quebec, Canada) in 2018 to 2019; and a “validation cohort” ( $n = 17$ ) at the Ataxia Clinic of the University Hospital Tübingen (Germany) in 2020 to 2021 (see Supplement for recruitment and

data collection). Patients in the discovery cohort were homozygous for the 8844delT mutation, except one compound heterozygous with a 7504C>T mutation, whereas the validation cohort covered a broad spectrum of mutations (Table S2). For the younger validation cohort, 19 healthy controls matched for sex, age, and education were selected from the larger German validation cohort of the CCAS scale.<sup>25</sup> Education was quantified by total years of schooling to ensure comparability across different education systems. Disease duration in the discovery cohort was approximated by age given the uniform onset with early motor developmental delay around age 1 year.

The CCAS scale was used to screen for neuropsychological deficits.<sup>26</sup> This scale comprises 10 subtests, each rated as “passed” or “failed” according to a cutoff score (see Supplement S3 for details of outcome measures). The sum of raw scores for each subtest yields a total score, with a score of  $\geq 82$  considered normal (maximum = 120).<sup>9</sup> The number of failed subtests determines the likelihood of CCAS: 1 = “possible CCAS”; 2 = “probable CCAS”; and 3 = “definite CCAS.”<sup>9</sup> To account for false positives, the number of failed tests in the validation cohort was also compared against individual cutoffs adjusted for age, sex, and education, which have been modelled for German cohorts.<sup>27</sup> The Friedreich Ataxia Rating Scale (FARS) functional staging was used as global disease severity staging (0 = normal to 6 = wheelchair/total disability). The Scale for the Assessment and Rating of Ataxia (SARA) was used to assess the severity of the motor syndrome of ARSACS.<sup>28</sup> In the validation cohort, the Montreal Cognitive Assessment (MoCA) was applied as an independent, well-established, and more global neuropsychological screening tool 1 to 2 hours before the CCAS scale.

Descriptive results are presented as median (interquartile range), or frequency (percentage). Fisher’s exact test and Mann–Whitney tests were used to compare categorical and continuous variables, respectively, and Spearman correlation to explore associations between scores and demographic/clinical variables, all with SPSS Version 30.0 (IBM; Armonk, NY).

## Results

In the discovery cohort (age: 57 [54–62] years; education: 11 [9–12] years), the median CCAS total score

**TABLE 1** Characteristics of participants

Characteristics	ARSACS cohort			Cohort comparisons ( <i>P</i> -value) <sup>a</sup>	
	Discovery cohort (n = 31)	Validation cohort (n = 17)	Control cohort (n = 19)	Discovery vs. validation	Validation vs. control
Sex, n (%)					
Men	17 (54.8)	11 (64.7)	9 (47.4)	0.555	0.335
Women	14 (45.2)	6 (35.3)	10 (52.6)		
Age, yr; median (IQR) [range]	57 (54–62) [51–66]	35 (21–43) [14–58]	40 (25–48) [19–77]	<0.001	0.350
Education, yr; median (IQR) [range]	11 (9–12) [0–17]	10 (9–11) [7–14]	10 (10–10) [9–17]	0.285	0.456
Disease duration, yr; median (IQR) [range]	57 (54–62) <sup>f</sup> [51–66]	22 (15–30) [12–52]	Not applicable	–	–
Mobility level, n (%)					
No walking difficulty	0 (0)	0 (0)	Not available	<0.001	–
Walking difficulty, no walking aid	0 (0)	5 (29.4)			
Walk with aid and support	2 (6.5)	8 (47.1)			
Wheelchair user	29 (93.5)	4 (23.5)			
FARS stage; median (IQR) [range]	5 (5–6) [4–6]	4 (2–5) [1–5]	Not applicable	<0.001	–
SARA <sup>b</sup> ; median (IQR) [range]	32 (27–35) [18–40]	16 (11–26) [3–33]	Not applicable	<0.001	–
MoCA <sup>c</sup> ; median (IQR) [range]	Not available	22.4 (3.8) [12–26]	Not available	–	–
CCAS					
Total score <sup>d</sup> ; median (IQR) [range]	40 (25–52) [10–64]	81 (67–86) [37–93]	101 (91–106) [91–112]	<0.001	<0.001
Failed test <sup>e</sup> ; median (IQR) [range]	8 (8–10) [5–10]	5 (3–7) [3–10]	1 (1–2) [0–4]	<0.001	<0.001
Definite CCAS, n (%)	31 (100)	17 (100)	3 (16)	–	–
Probable CCAS, n (%)	0 (0)	0 (0)	5 (26)	–	–
Possible CCAS, n (%)	0 (0)	0 (0)	7 (37)	–	–
>1 failed test above cutoff adjusted for age, sex, and education	Not available	16 (94%)	3 (16%)	–	<0.001

<sup>a</sup>Comparisons of variables between cohorts were made using the Fisher’s exact test for sex and mobility level proportions and Mann–Whitney test for age, education, SARA, FARS stage, and CCAS total score and failed tests.

<sup>b</sup>SARA maximum score is 40.

<sup>c</sup>MoCA maximum score is 30.

<sup>d</sup>CCAS total score is 120.

<sup>e</sup>CCAS total number of tests is 10.

<sup>f</sup>Represented by age, given development onset.

Abbreviations: ARSACS, autosomal recessive spastic ataxia of Charlevoix-Saguenay; IQR, interquartile range; FARS, Friedreich Ataxia Rating Scale; SARA, Scale for the Assessment and Rating of Ataxia; MoCA, Montreal Cognitive Assessment.

was 40 [25–52], and all 31 participants failed ≥5/10 subtests, indicating “definite CCAS” for the entire cohort (Table 1). Eight participants (25%) failed all 10 subtests. Five subtests (semantic fluency, phonemic fluency, category switching, 3D draw/copy, and digit span forward) were failed by ≥90% of the discovery cohort (Table 2).

The 17 participants in the validation cohort were younger and presented at an earlier ataxia stage than the discovery cohort (age: 35 [21–43] years; SARA: 16 [11–26], both *P* < 0.001), but also showed reduced CCAS total scores of 81 [67–86] (Table 1)—although this reduction was less pronounced than in the older, later-stage discovery cohort (*P* < 0.001). All

**TABLE 2** Performances in each CCAS scale component for all participants

CCAS components	Total score median (IQR)			Cohort comparisons (P-value) <sup>a</sup>		No. of participants who failed n (%)			Cohort comparisons (P-value) <sup>b</sup>	
	Discovery cohort (n = 31)	Validation cohort (n = 17)	Control cohort (n = 19)	Discovery vs. validation	Validation vs. control	Discovery cohort (n = 31)	Validation cohort (n = 17)	Control cohort (n = 19)	Discovery vs. validation	Validation vs. control
Semantic fluency (/26)	5 (3–7)	16 (12.5–19)	24 (20–26)	0.015	<0.001	31 (100)	7 (41)	0 (0)	<0.001	0.005
Phonemic fluency (/19)	3 (1–5)	7 (5–8.5)	12 (9–14)	0.002	<0.001	30 (96.8)	14 (82)	4 (21)	0.191	0.004
Category switching (/15)	1 (0–2)	10 (7.5–12)	12 (9–15)	0.011	0.052	31 (100)	8 (47)	5 (26)	<0.001	0.374
Digit span forward (/8)	4 (3–4)	4 (4–5.5)	7 (6–7)	0.047	<0.001	28 (90.3)	13 (77)	4 (21)	0.251	0.005
Digit span backward (/6)	3 (2–3)	3 (2.5–4.5)	4 (3–5)	0.015	0.431	26 (83.9)	9 (53)	7 (37)	0.079	0.503
3D draw/copy (/15)	6 (3–9)	13 (10–15)	15 (12–15)	<0.001	0.118	29 (93.5)	7 (41)	1 (5)	<0.001	0.026
Verbal delayed recall (/15)	7 (4–10)	14 (10.5–15)	14 (13–14)	<0.001	0.811	21 (67.7)	4 (24)	1 (5)	0.015	0.234
Similarities (/8)	2 (2–6)	6 (5–7)	8 (8–8)	0.001	<0.001	27 (87.1)	11 (65)	0 (0)	0.191	<0.001
Go/no-go (/2)	1 (0–2)	2 (0–2)	1 (1–2)	0.543	0.931	16 (51.6)	6 (35)	4 (21)	0.368	0.503
Affect (/6)	4 (3–5)	5 (2.5–5.5)	6 (6–6)	0.574	<0.001	21 (67.7)	8 (47)	0 (0)	0.251	0.004

<sup>a</sup>Comparison between cohorts using Mann–Whitney test, with Benjamini–Hochberg correction for multiple comparisons.

<sup>b</sup>Comparison between cohorts using Fisher’s exact test, with Benjamini–Hochberg correction for multiple comparisons.

Abbreviations: CCAS, cerebellar cognitive-affective syndrome; IQR, interquartile range.

participants failed  $\geq 3$  of 10 subtests, indicating “definite CCAS” for the entire validation cohort, as for the discovery cohort. Although failure rates across subtests were generally lower than in the discovery cohort, phonemic fluency and digit span forward were still failed by at least 75% of the validation cohort (Table 2).

CCAS total scores in the validation cohort were also lower (81 [67–86] vs. 101 [91–106],  $P < 0.001$ ), and the number of failed subtests was higher than in matched controls (5 [3–7] vs. 1 [1–2];  $P < 0.001$ ) (Table 1). In a control analysis, 16 of 17 ARSACS participants (94%) also exceeded their individual CCAS cutoffs adjusted for age, sex, and education—as compared to 3 of 19 controls.

CCAS total scores were correlated to disease duration as well as FARS stage and SARA scores as measures of ataxia severity—both in the discovery cohort ( $\rho = -0.58$ ,  $\rho = -0.37$ , and  $\rho = -0.53$ ;  $P < 0.041$ ) and validation cohort ( $\rho = -0.53$ ,  $\rho = -0.62$ , and  $\rho = -0.51$ ;  $P < 0.037$ ). Education was correlated with CCAS total scores in the older discovery cohort (Table S4).

Both CCAS total scores and the number of failed subtests were highly correlated with the MoCA score ( $\rho = 0.88$  and  $\rho = -0.79$ ;  $P < 0.001$ ). The MoCA indicated severe cognitive impairment in 1 of 15 participants (12 points), mild cognitive impairment in 10 of 15 (19–25 points), and cognitive levels in the low-normal range (26 points) in the remaining participants. Correlations of the MoCA score with disease duration or ataxia severity were not significant (Table S4).

The most frequent neuropsychiatric feature in the CCAS subtest “affect” was difficulty with focusing attention or mental flexibility, both in the discovery cohort (87%) and the validation cohort (59%). Emotional lability and irritability/aggressiveness were also highly prevalent neuropsychiatric features (~40%), followed by lack of empathy, apathy, or blunted affect (25–30%) (Supplement S5, including also discussion of interview results).

## Discussion

This study assessed neuropsychological deficits in ARSACS by applying the CCAS scale to geographically, genetically, and clinically distinct cohorts in a bi-center discovery plus validation cohort design. As major finding, we showed that all examined patients failed in multiple subtests of the CCAS scale, therefore, indicating “definite CCAS” as consistent neuropsychological deficit in ARSACS—at least in our cohorts. Given also the increased number of failed subtests and lower CCAS total scores in comparison to matched controls, and robust findings after adjustment for age, education, and sex, the detected neuropsychological deficits in

ARSACS were not false positives (eg, because of higher age or lower education). Rather, they likely presented a genuine and—given the younger age of the validation cohort—relatively early feature of ARSACS.

Our results also suggest that CCAS-related neuropsychological deficits are progressive in ARSACS, as the number of failed subtests was higher, and the total score lower in the (older/later-stage) discovery cohort than in the (younger/earlier-stage) validation cohort. This difference in severity was likely driven by more advanced neurodegeneration, as it was paralleled by differences in ataxia severity (FARS stage, SARA), which was correlated with the CCAS total score.

Qualitatively, five subtests were failed by  $\geq 90\%$  of the discovery cohort: semantic fluency, phonemic fluency, category switching, 3D draw/copy, and digit span forward. These deficits relate to language, executive functions, visuospatial abilities, working memory, and attention, and are consistent with cognitive deficits suggestive of CCAS reported for heterogeneous cerebellar patients,<sup>10,12</sup> as well as in small case studies of ARSACS.<sup>5,7,29</sup> Quantitatively, however, CCAS total scores in our ARSACS cohorts were lower, and therefore, neuropsychological deficits more severe than in other cerebellar ataxias.<sup>10,30</sup> Notably, deficits were comparable to spinocerebellar ataxia type 2 and RFC1-disease with milder ataxia severity, but substantial extra-cerebellar involvement.<sup>17,31–33</sup> Furthermore, 68% of patients in the discovery cohort had impaired verbal recall, which presents a non-cerebellar cognitive domain. Together, this suggests that the severe neuropsychological deficits in ARSACS are probably not caused by cerebellar dysfunction only, but rather reflect additional extra-cerebellar involvement. Besides parietal atrophy on structural magnetic resonance imaging (MRI),<sup>2,34</sup> widespread reduction of supratentorial white matter volume and microstructural integrity of large associative fiber bundles (including the corpus callosum) have recently been shown in ARSACS by diffusion MRI.<sup>35</sup> Borderline correlations of the corresponding diffusion metrics with the MoCA further indicate that extra-cerebellar involvement contributes to the neuropsychological deficits in ARSACS<sup>35</sup>—in particular, because the MoCA putatively lacks sensitivity for CCAS caused by relatively “pure” cerebellar damage.<sup>10</sup>

Although our validation cohort covered the genetic diversity of ARSACS worldwide,<sup>2</sup> and therefore, enhanced generalizability, we cannot exclude that neuropsychological differences between cohorts may be partly attributable to different genotypes rather than disease progression alone. Furthermore, we did not explore whether application of the CCAS scale was affected by prior MoCA assessment or by motor impairment (eg, assessment of fluency by dysarthria<sup>36</sup> or drawing by incoordination and/or weakness).

Finally, non-inclusion of pediatric patients and patients with intellectual disability or severe cognitive impairment (lack of informed consent) may have limited insights across the full age spectrum, including the onset of neuropsychological deficits. In pediatric ARSACS, viewed as combined neurodevelopmental and neurodegenerative disorder, intellectual disability may represent one end of a spectrum of developmental cognitive and affective dysfunctions, detectable in approximately 50% of patients.<sup>37</sup> In older ARSACS patients, it remains to be demonstrated to what extent age (or co-pathology) exacerbates cognitive impairment, independent of ARSACS pathology.

In conclusion, our study highlights that neuropsychological deficits consistent with CCAS are a consistent, early, and progressive feature of ARSACS. Future studies combining in-depth neuropsychological assessments with neuroimaging studies are warranted to chart the evolution across the full age spectrum and to relate neuropsychological deficits to cerebellar versus extra-cerebellar involvement in ARSACS.<sup>35</sup> ■

**Author Roles:** Research Project: (1) A. Conception and Design, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the First Draft, B. Review and Critique.

J.F.: 1B, 1C, 3A, 3B.

M.S.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B.

E.P.T.: 1A, 1B, 1C, 3A, 3B.

D.H.: 2C, 3B.

A.T.: 2C, 3B.

D.T.: 2C, 3B.

R.L.P.: 1C.

B.B.: 1A, 3B.

J.D.: 1A.

I.C.: 2A, 2B, 2C, 3A, 3B.

C.G.: 1A, 1B, 1C, 2A, 2C, 3B.

A.T.: 1A, 1B, 1C, 2A, 2B, 2C, 3A, 3B.

## Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request following the proper evaluation of the research protocol by the ethics review boards of the Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay-Lac-St-Jean (Saguenay, Québec, Canada) and University of Tübingen (Germany). The data are not publicly available because of privacy or ethical restrictions.

## References

1. Traschütz AA-O, Adarmes-Gomez AD, Anheim M, et al. Autosomal recessive cerebellar ataxias in Europe: Frequency, onset, and severity in 677 Patients. *Mov Disord* 2023;38:1109–1112.
2. Synofzik M, Soehn AS, Gburek-Augustat J, et al. Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. *Orphanet J Rare Dis* 2013;8:41.
3. Gagnon C, Brais B, Lessard I, Lavoie C, Côté I, Mathieu J. From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay. *Orphanet J Rare Dis* 2018;13:165.

4. Vermeer S, van de Warrenburg BP, Kamsteeg EJ, Brais B, Synofzik M. ARSACS. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*(R). Seattle (WA): University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle; 1993.
5. Verhoeven WM, Egger JI, Ahmed AI, Kremer BP, Vermeer S, van de Warrenburg BP. Cerebellar cognitive affective syndrome and autosomal recessive spastic ataxia of Charlevoix-Saguenay: a report of two male sibs. *Psychopathology* 2012;45:193–199.
6. Mignarri A, Tessa A, Carluccio MA, et al. Cerebellum and neuropsychiatric disorders: insights from ARSACS. *Neurol Sci* 2014;35:95–97.
7. Krygier M, Konkel A, Schinwelski M, et al. Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) – a polish family with novel SACS mutations. *Neurol Neurochir Pol* 2017;51:481–485.
8. Forgues G. Description des traits de personnalité et de l'adaptation sociale chez des personnes atteintes d'ataxie récessive spastique de Charlevoix-Saguenay [Doctoral dissertation]. Saguenay, Québec, Canada: Université du Québec à Chicoutimi; 2019.
9. Brassard K. Évaluation des capacités cognitives et de la participation sociale d'individus atteints d'ataxie récessive spastique de Charlevoix-Saguenay [Doctoral dissertation]. Saguenay, Québec, Canada: Université du Québec à Chicoutimi; 2020.
10. Hoche F, Guell X, Vangel MG, Sherman JC, Schmähmann JD. The cerebellar cognitive affective/Schmähmann syndrome scale. *Brain* 2018;141:248–270.
11. Schmähmann JD. Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. *J Neuropsychiatry Clin Neurosci* 2004;16:367–378.
12. Schmähmann JD, Sherman JC. The cerebellar cognitive affective syndrome. *Brain* 1998;121(Pt 4):561–579.
13. Agarwal A, Kaur H, Agarwal A, et al. Cognitive impairment in spinocerebellar ataxia type 12. *Parkinsonism Relat Disord* 2021;85:52–56.
14. Bürk K, Globas C, Bösch S, Klockgether T, Zühlke C, Daum J, Dichgans J. Cognitive deficits in spinocerebellar ataxia type 1, 2, and 3. *J Neurol* 2003;250:207–211.
15. Suenaga M, Kawai Y, Watanabe H, et al. Cognitive impairment in spinocerebellar ataxia type 6. *J Neurol Neurosurg Psychiatry* 2008;79:496–499.
16. Chirino-Pérez A, Vaca-Palomares I, Torres DL, Hernandez-Castillo CR, Diaz R, Ramirez-Garcia G, Fernandez-Ruiz J. Cognitive impairments in spinocerebellar ataxia type 10 and their relation to cortical thickness. *Mov Disord* 2021;36:2910–2921.
17. Rodríguez-Labrada R, Batista-Izquierdo A, González-Melix Z, et al. Cognitive decline is closely associated with ataxia severity in spinocerebellar ataxia type 2: a validation study of the Schmähmann syndrome scale. *Cerebellum* 2021;21:391–403.
18. Soares IFZ, Ciarlariello VB, Feder D, Carvalho AADS. Cognitive dysfunction and psychosis: expanding the phenotype of SPG7. *Neurocase* 2021;27:253–258.
19. Ringman JM, Qiao Y, Garbin A, et al. Emotional detachment, gait ataxia, and cerebellar dysconnectivity associated with compound heterozygous mutations in the SPG7 gene. *Neurocase* 2020;26:299–304.
20. Hoche F, Daly MP, Chutake YK, Valera E, Sherman JC, Schmähmann JD. The cerebellar cognitive affective syndrome in ataxia-telangiectasia. *Cerebellum* 2019;18:225–244.
21. la De Cruz Córdoba EA, González Medrano JA, Herrera Mora P, Gómez-Garza G, González-Serrano ME, Yamazaki-Nakashimada MA, Correa-Ramírez CA. Cerebellar cognitive affective syndrome in Mexican pediatric patients with ataxia-telangiectasia. *Cerebellum* 2024;23:363–373.
22. Destrebecq V, Comet C, Deveylder F, Alaerts N, Naeije G. Determinant of the cerebellar cognitive affective syndrome in Friedreich's ataxia. *J Neurol* 2023;270:2969–2974.
23. Karamazovova S, Stovickova L, Jester DJ, et al. Exploring neuropsychiatric symptoms in Friedreich ataxia. *Sci Rep* 2024;14:29076.

24. Tremblay M, Laberge L, Maltais D, Durand MJ, Chouinard MC, Gagnon C. Accès et intégration en emploi chez les personnes atteintes d'ataxie récessive spastique de Charlevoix-Saguenay: le rôle de l'ergothérapeute. Vol. 76. ErgoThérapies; 2020.
25. Thieme A, Roeske S, Faber J, et al. Validation of a German version of the cerebellar cognitive affective/ Schmahmann syndrome scale: preliminary version and study protocol. *Neurol Res Pract* 2020; 2:39.
26. Schmahmann JD. The cerebellum and cognition. *Neurosci Lett* 2019;688:62–75.
27. Thieme A, Rubarth K, van der Veen R, et al. Optimizing selectivity of the cerebellar cognitive affective syndrome scale by use of correction formulas, and validation of its German version. *J Neurol* 2025; 272:343.
28. Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. *Neurology* 2006;66:1717–1720.
29. Boucher A. Étude exploratoire des fonctions cognitives chez les individus âgés de 41 à 60 ans atteints d'ataxie récessive spastique de Charlevoix-Saguenay (ARSCS). Chicoutimi, Canada: UQAC; 2017.
30. Thieme A, Faber J, Sulzer P, et al. The CCAS-scale in hereditary ataxias: helpful on the group level, particularly in SCA3, but limited in individual patients. *J Neurol* 2022;269:4363–4374.
31. Dujardin K, Tard C, Diglé E, et al. Cognitive impairment is part of the phenotype of cerebellar ataxia, neuropathy, vestibular Areflexia syndrome (CANVAS). *Mov Disord* 2024;39:892–897.
32. Jung BC, Choi SI, Du AX, et al. MRI shows a region-specific pattern of atrophy in spinocerebellar ataxia type 2. *Cerebellum* 2012;11: 272–279.
33. Matos P, Rezende TJR, Schmitt GS, et al. Brain structural signature of RFC1-related disorder. *Mov Disord* 2021;36:2634–2641.
34. Rezende Filho FM, Parkinson MH, Pedrosa JL, et al. Clinical, ophthalmological, imaging and genetic features in Brazilian patients with ARSACS. *Parkinsonism Relat Disord* 2019;62:148–155.
35. Scaravilli A, Gabusi I, Mari G, et al. An MRI evaluation of white matter involvement in paradigmatic forms of spastic ataxia: results from the multi-center PROSPAX study. *J Neurol* 2024;271:5468–5477.
36. Corben LA, Blomfield E, Tai G, et al. The role of verbal fluency in the cerebellar cognitive affective syndrome scale in Friedreich ataxia. *Cerebellum (London, England)* 2024;23:1975–1980.
37. Pilliod J, Moutton S, Lavie J, et al. New practical definitions for the diagnosis of autosomal recessive spastic ataxia of Charlevoix-Saguenay. *Ann Neurol* 2015;78:871–886.

## Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.